Fennec Pharmaceuticals INC.: insider trades · United States · SEC (Form 4)

About Fennec Pharmaceuticals INC.

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company listed on the NASDAQ (ticker: FENC) in the United States. The company is headquartered in Research Triangle Park, North Carolina, and it focuses on a highly specific oncology-supportive-care niche: reducing cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. Its core asset is PEDMARK® (sodium thiosulfate injection), which received FDA approval in September 2022 and began U.S. commercial availability in October 2022. Outside the United States, the same product is marketed as PEDMARQSI®, with approvals in Europe and the United Kingdom, giving Fennec a broader international runway than its domestic profile alone might suggest.([investors.fennecpharma.com](https://investors.fennecpharma.com/?utm_source=openai)) From a corporate history standpoint, Fennec was originally incorporated in British Columbia under the name Adherex Technologies Inc. and later changed its name to Fennec Pharmaceuticals Inc. in 2014. That evolution matters for investors because it reflects a transition from earlier-stage development activities toward a commercial-stage model anchored by one lead branded therapy. Today, the company’s business is concentrated almost entirely on PEDMARK in the U.S. market, supported by the Fennec HEARS™ patient-support platform, which is designed to help families and providers navigate access, reimbursement, and treatment logistics.([sec.gov](https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm?utm_source=openai)) In competitive terms, Fennec is a focused, specialty player rather than a broad-based oncology company. It is not built around a large diversified pipeline; instead, the investment case depends on the clinical and commercial adoption of a single differentiated product in a well-defined hospital setting. That creates both concentration risk and strategic clarity. The company’s moat is tied to regulatory approvals, the clinical relevance of preventing hearing loss in children receiving cisplatin, and the ability to expand use within oncology care pathways. Internationally, Fennec has extended its reach through licensing rather than direct commercial buildout: in March 2024 it signed an exclusive agreement with Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand, which broadens geographic exposure while limiting capital intensity.([sec.gov](https://www.sec.gov/Archives/edgar/data/1211583/000155837025003710/fencf-20241231x10k.htm?utm_source=openai)) Recent developments have been supportive. In March 2026, Fennec reported record full-year 2025 net product sales and described continued quarter-over-quarter growth during 2025. In 2025, it also disclosed positive topline results from an investigator-initiated study in Japan evaluating PEDMARK for cisplatin-induced hearing loss, and it announced additional research collaborations with leading U.S. cancer institutions such as City of Hope and Tampa General Hospital Cancer Institute. For investors, these updates suggest a company moving beyond first commercialization in the United States toward broader evidence generation and potential label/market expansion, while still retaining the risk profile of a small-cap single-product pharmaceutical business.([investors.fennecpharma.com](https://investors.fennecpharma.com/news-releases/news-release-details/fennec-pharmaceuticals-reports-fourth-quarter-and-full-year-2025?utm_source=openai))